Loading...
XHKG
1110
Market cap28mUSD
Oct 09, Last price  
0.39HKD
1D
1.32%
1Q
-2.53%
Jan 2017
-68.70%
IPO
-84.60%
Name

Kingworld Medicines Group Ltd

Chart & performance

D1W1MN
XHKG:1110 chart
P/E
17.17
P/S
0.21
EPS
0.02
Div yield, %
8.34%
Shrs. gr., 5y
-0.94%
Rev. gr., 5y
4.24%
Revenues
917m
-13.55%
556,417,000638,046,000685,562,000705,519,000554,763,000660,323,000713,548,0001,053,527,0001,031,488,0001,078,843,000977,928,000745,383,000847,386,000957,701,0001,078,659,0001,061,082,000917,341,000
Net income
11m
-72.85%
37,244,00042,863,00051,031,00048,535,00047,177,00037,865,00031,205,00046,966,00051,060,00041,005,00043,427,00011,716,00030,319,00022,741,00038,096,00041,557,00011,282,000
CFO
85m
-37.74%
158,647,00013,416,000-53,326,00073,203,000-49,849,000-5,230,000102,790,000-2,207,00072,388,00062,385,000132,711,000123,584,00081,199,000186,548,00042,284,000135,820,00084,559,000
Dividend
Jun 05, 20250.0317 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.

Key people

Li Sheng Zhao
Executive Chairman of the Board, Chief Executive Officer · since 2015
Financial Controller, Company Secretary, Authorised Representative · since 2009
Lok San Chan
Executive Director · since 2008
Xuhua Zhou
General Manager of SZ Kingworld, Executive Director · since 2009
Yun Ceng
Sales Controller - Commerce of SZ Kingworld · since 2015
Yong Chen
Manager - Finance Department of SZ Kingworld · since 2021
Yueyue Chen
Controller of SZ Kingworld, East China · since 2021
Jia Zhi Fang
Manager - Investment Center · since 2021
Danna Fang
Financial Manager of SZ Kingworld · since 1995
Ruozhong Huang
Corporate Finance Controller of SZ Kingworld
Zhihui Huang
Manager - Audit and Supervision Center · since 2021
Yibing Liu
Assistant of the General Manager of SZ Kingworld · since 2013
Jinwu Liu
Deputy Controller - Pharmaceutical Department of SZ Kingworld · since 2021
Hui Wang
Executive Controller - Human Resource Center of SZ Kingworld · since 2021
Yaoliang Xie
Executive Sales and Marketing General Manager of SZ Kingworld · since 2021
Guang Qian Xing
Controller, Zhejiang-Shanghai Region of SZ Kingworld · since 2021
Kin Wai Zhao
Assistant to the Chairman · since 2021
Xiaoping Chu
Non-Executive Independent Director · since 2024
Independent Non-Executive Director · since 2010
Cheuk Lam Wong
Independent Non-Executive Director · since 2010
IPO date
Nov 25, 2010
Employees
1,019
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT